{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:48:16Z","timestamp":1791910096227,"version":"4.3.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      We describe the prevalence of macrolide-resistant\n                      <jats:italic toggle=\"yes\">Mycoplasma pneumoniae<\/jats:italic>\n                      (MRMP)-induced pediatric community-acquired pneumonia (CAP) in Bangkok, Thailand.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Nasopharyngeal aspirates were prospectively collected from children and adolescents 0\u201318 years of age with chest radiograph-confirmed CAP between January 2014 and January 2020 at a single tertiary-care center in Bangkok, Thailand.\n                      <jats:italic toggle=\"yes\">M. pneumoniae<\/jats:italic>\n                      was identified from nasopharyngeal aspirates using real-time polymerase chain reaction (RT-PCR). Macrolide-resistant mutations, including A2063G, A2064G, A2067G and C2617G in the 23S rRNA gene, were identified through PCR-sequencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 332 patients with CAP, 55 (16.6%) had\n                      <jats:italic toggle=\"yes\">M. pneumoniae<\/jats:italic>\n                      infection. Among those with mycoplasmal pneumonia, the median age (range) was 8.3 years (1.2\u201317.5), and 30 (54.5%) were female. Twenty-five patients (45.5%) developed complications, including 12 (21.8%) cases of pleural effusion, 10 (18.1%) cases of skin rashes, 6 (10.9%) cases of hematologic complications, 2 (3.6%) cases of transaminitis, and 1 (1.8%) case of respiratory failure. Of the 36 patients who underwent genotyping, 8 (22.2%) carried macrolide-resistant mutations\u2014all A2063G mutations. Compared with those without macrolide-resistant mutations, patients with MRMP had a longer time to defervescence after antimicrobial therapy (3.0 vs. 5.5 days,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). Patients with and without macrolide-resistant mutations had similar rates of previous exposure to macrolide antibiotics, durations of fever and cough, rates of complications, frequency of oxygen supplementation requirements, lengths of hospitalization and macrolide treatment failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>About 1 in 5 children and adolescents with mycoplasmal CAP in Thailand have infections caused by MRMP, which result in a longer time to defervescence after therapy. Monitoring MRMP is crucial to establish local treatment strategies for pediatric CAP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005147","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:00:29Z","timestamp":1769144429000},"page":"598-601","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of Macrolide-resistant Mycoplasma pneumoniae in Children and Adolescents With Community-acquired Pneumonia: A Prospective Study in Thailand"],"prefix":"10.1097","volume":"45","author":[{"given":"Wanatpreeya","family":"Phongsamart","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korakrit","family":"Imwattana","sequence":"additional","affiliation":[{"name":"Department of Microbiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukrapun","family":"Siriboriruk","sequence":"additional","affiliation":[{"name":"Department of Microbiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarachai","family":"Kiratisin","sequence":"additional","affiliation":[{"name":"Department of Microbiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-4600","authenticated-orcid":false,"given":"Kulkanya","family":"Chokephaibulkit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics"},{"name":"Siriraj Institute of Clinical Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"R1-20260609","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/cid\/ciy419","article-title":"Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia.","volume":"68","author":"Kutty","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R2-20260609","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/cid\/ciy421","article-title":"Mycoplasma pneumoniae as a cause of community-acquired pneumonia in children.","volume":"68","author":"Shah","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R3-20260609","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2147\/IDR.S193076","article-title":"Detection of Mycoplasma pneumoniae in Mexican children with community-acquired pneumonia: experience in a tertiary care hospital.","volume":"12","author":"Merida-Vieyra","year":"2019","journal-title":"Infect Drug Resist"},{"key":"R4-20260609","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3345\/cep.2022.01452","article-title":"Community-acquired pneumonia in children: updated perspectives on its etiology, diagnosis, and treatment.","volume":"67","author":"Yun","year":"2023","journal-title":"Clin Exp Pediatr"},{"key":"R5-20260609","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5409\/wjcp.v12.i3.115","article-title":"Clinical characteristics of community-acquired pneumonia in children caused by Mycoplasma pneumoniae with or without myocardial damage: a single-center retrospective study.","volume":"12","author":"Yusuf","year":"2023","journal-title":"World J Clin Pediatr"},{"issue":"Suppl 3","key":"R6-20260609","first-page":"S124","article-title":"Mycoplasma pneumonia in young children, 2-5 years of age.","volume":"91","author":"Bunnag","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"R7-20260609","first-page":"1412","article-title":"Prevalence and clinical presentations of atypical pathogens infection in community acquired pneumonia in Thailand.","volume":"89","author":"Prapphal","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"R8-20260609","first-page":"814","article-title":"Mycoplasma pneumoniae and Chlamydophila pneumoniae in children with community-acquired pneumonia in Thailand.","volume":"11","author":"Lochindarat","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"R9-20260609","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7883\/yoken.JJID.2008.36","article-title":"Prevalence of Mycoplasma and chlamydia pneumonia in severe community-acquired pneumonia among hospitalized children in Thailand.","volume":"61","author":"Samransamruajkit","year":"2008","journal-title":"Jpn J Infect Dis"},{"key":"R10-20260609","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2666-5247(23)00344-0","article-title":"Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.","volume":"5","author":"Sauteur","year":"2024","journal-title":"Lancet Microbe"},{"key":"R11-20260609","doi-asserted-by":"crossref","first-page":"1427702","DOI":"10.3389\/fmicb.2024.1427702","article-title":"An outbreak of Mycoplasma pneumoniae in children after the COVID-19 pandemic, Shanghai, China, 2023.","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Microbiol"},{"key":"R12-20260609","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment.","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"R13-20260609","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3201\/eid2108.150273","article-title":"Macrolide-resistant mycoplasma pneumoniae, United States.","volume":"21","author":"Zheng","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"R14-20260609","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1128\/AAC.00663-13","article-title":"Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20260609","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3201\/eid2310.170106","article-title":"Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008-2015.","volume":"23","author":"Tanaka","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R16-20260609","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3201\/eid2607.200017","article-title":"Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia.","volume":"26","author":"Chen","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"R18-20260609","doi-asserted-by":"crossref","first-page":"e0174701","DOI":"10.1371\/journal.pone.0174701","article-title":"Comprehensive bioinformatics analysis of Mycoplasma pneumoniae genomes to investigate underlying population structure and type-specific determinants.","volume":"12","author":"Diaz","year":"2017","journal-title":"PLoS One"},{"key":"R19-20260609","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/AAC.04308-14","article-title":"Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China.","volume":"59","author":"Zhou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20260609","first-page":"PA2614","article-title":"Macrolide-resistant Mycoplasma pneumoniae in respiratory tract infection and its clinical relevance.","volume":"48","author":"Domthong","year":"2016","journal-title":"Eur Respiratory Soc"},{"key":"R21-20260609","doi-asserted-by":"crossref","first-page":"P2493","DOI":"10.1183\/13993003\/erj.44.Suppl_58.P2493","article-title":"Emerging macrolide-resistant Mycoplasma pneumoniae in Thailand.","volume":"44","author":"Domthong","year":"2014","journal-title":"Eur Respir J"},{"key":"R22-20260609","doi-asserted-by":"crossref","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis.","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R23-20260609","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jmii.2018.09.009","article-title":"Mycoplasma pneumoniae in pediatric patients: do macrolide-resistance and\/or delayed treatment matter?","volume":"52","author":"Yang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"R24-20260609","doi-asserted-by":"crossref","first-page":"1449511","DOI":"10.3389\/fmicb.2024.1449511","article-title":"Increased macrolide resistance rate of Mycoplasma pneumoniae correlated with epidemic in Beijing, China in 2023.","volume":"15","author":"Chen","year":"2024","journal-title":"Front Microbiol"},{"key":"R25-20260609","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jiac.2020.10.007","article-title":"Recent acute reduction in macrolide-resistant Mycoplasma pneumoniae infections among Japanese children.","volume":"27","author":"Nakamura","year":"2021","journal-title":"J Infect Chemother"},{"key":"R26-20260609","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3345\/kjp.2017.60.5.151","article-title":"Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children.","volume":"60","author":"Lee","year":"2017","journal-title":"Korean J Pediatr"},{"key":"R27-20260609","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond.","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R28-20260609","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3201\/eid2706.203206","article-title":"Macrolide-Resistant Mycoplasma pneumoniae infections in children, Ohio, USA.","volume":"27","author":"Lanata","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"R29-20260609","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12879-017-2500-z","article-title":"Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia.","volume":"17","author":"Yoon","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R30-20260609","doi-asserted-by":"crossref","first-page":"e0173635","DOI":"10.1371\/journal.pone.0173635","article-title":"Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.","volume":"12","author":"Ishiguro","year":"2017","journal-title":"PLoS One"},{"key":"R31-20260609","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10156-009-0021-4","article-title":"Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia.","volume":"16","author":"Morozumi","year":"2010","journal-title":"J Infect Chemother"},{"key":"R32-20260609","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4168\/aair.2017.9.4.340","article-title":"Macrolide resistance and its impacts on M. pneumoniae pneumonia in children: comparison of two recent epidemics in Korea.","volume":"9","author":"Kim","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"R33-20260609","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/crj.12379","article-title":"Overview of antimicrobial options for M ycoplasma pneumoniae pneumonia: focus on macrolide resistance.","volume":"11","author":"Cao","year":"2017","journal-title":"Clin Respir J"},{"key":"R34-20260609","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00968-19","article-title":"Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program.","volume":"57","author":"Waites","year":"2019","journal-title":"J Clin Microbiol"},{"key":"R35-20260609","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.01806-13","article-title":"More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.","volume":"58","author":"Zhou","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:58Z","timestamp":1780977658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005147","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}